The clinical potential of chemokine receptor antagonists

Pharmacol Ther. 2005 Jul;107(1):44-58. doi: 10.1016/j.pharmthera.2005.01.004.

Abstract

Chemokines belong to a family of chemotactic cytokines that direct the migration of immune cells towards sites of inflammation. They mediate their biological effects by binding to cell surface receptors, which belong to the G protein-coupled receptor superfamily. Since chemokines and their receptors have been implicated in the pathophysiology of a number of autoinflammatory diseases, chemokine receptor antagonists could prove to be useful therapeutics to target these diseases. Here, we review the role of chemokines in autoimmunity, concentrating mainly on the chemokine receptors CCR1 and CCR5, and discuss the potential utility of antagonists that target these 2 receptors as they progress through the clinic.

Publication types

  • Review

MeSH terms

  • Animals
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / metabolism
  • Arthritis, Rheumatoid / physiopathology
  • Autoimmune Diseases* / drug therapy
  • Autoimmune Diseases* / immunology
  • Autoimmune Diseases* / metabolism
  • CCR5 Receptor Antagonists
  • Chemokines* / adverse effects
  • Chemokines* / metabolism
  • Chemokines* / physiology
  • Diabetes Mellitus / drug therapy*
  • Diabetes Mellitus / metabolism
  • Diabetes Mellitus / physiopathology
  • Endometriosis / drug therapy
  • Endometriosis / etiology
  • Endometriosis / physiopathology*
  • Female
  • Humans
  • Multiple Myeloma / drug therapy
  • Multiple Myeloma / etiology
  • Multiple Myeloma / physiopathology*
  • Receptors, CCR1
  • Receptors, Chemokine / antagonists & inhibitors

Substances

  • CCR1 protein, human
  • CCR5 Receptor Antagonists
  • Chemokines
  • Receptors, CCR1
  • Receptors, Chemokine